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ORIGINAL RESEARCH
Novel Plaque Enriched Long Noncoding RNA in 
Atherosclerotic Macrophage Regulation (PELATON)
John Hung,* Jessica P. Scanlon,* Amira D. Mahmoud,† Julie Rodor,† Margaret Ballantyne, Margaux A.C. Fontaine, Lieve Temmerman,  
Jakub Kaczynski, Katie L. Connor, Raghu Bhushan, Erik A.L. Biessen, David E. Newby, Judith C. Sluimer,‡ Andrew H. Baker‡
OBJECTIVE: Long noncoding RNAs (lncRNAs) are an emergent class of molecules with diverse functional roles, widely 
expressed in human physiology and disease. Although some lncRNAs have been identified in cardiovascular disease, their 
potential as novel targets in the prevention of atherosclerosis is unknown. We set out to discover important lncRNAs in 
unstable plaque and gain insight into their functional relevance.
APPROACH AND RESULTS: Analysis of RNA sequencing previously performed on stable and unstable atherosclerotic plaque 
identified a panel of 47 differentially regulated lncRNAs. We focused on LINC01272, a lncRNA upregulated in unstable 
plaque previously detected in inflammatory bowel disease, which we termed PELATON (plaque enriched lncRNA in 
atherosclerotic and inflammatory bowel macrophage regulation). Here, we demonstrate that PELATON is highly monocyte- 
and macrophage-specific across vascular cell types, and almost entirely nuclear by cellular fractionation (90%–98%). 
In situ hybridization confirmed enrichment of PELATON in areas of plaque inflammation, colocalizing with macrophages 
around the shoulders and necrotic core of human plaque sections. Consistent with its nuclear localization, and despite 
containing a predicted open reading frame, PELATON did not demonstrate any protein-coding potential in vitro. Functionally, 
knockdown of PELATON significantly reduced phagocytosis, lipid uptake and reactive oxygen species production in high-
content analysis, with a significant reduction in phagocytosis independently validated. Furthermore, CD36, a key mediator of 
phagocytic oxLDL (oxidized low-density lipoprotein) uptake was significantly reduced with PELATON knockdown.
CONCLUSIONS: PELATON is a nuclear expressed, monocyte- and macrophage-specific lncRNA, upregulated in unstable 
atherosclerotic plaque. Knockdown of PELATON affects cellular functions associated with plaque progression.
Key Words: atherosclerosis ◼ macrophage ◼ monocyte ◼ phagocytosis ◼ reactive oxygen species
Cardiovascular disease remains the world’s lead-ing cause of mortality, resulting in over 17 million deaths each year.1 This global epidemic is largely 
caused by atherosclerosis, a chronic inflammatory dis-
ease of the vasculature characterized by development of 
plaque in the arterial wall. Atherosclerosis accounts for 
>3 quarters of cardiovascular mortality in both high and 
low-income countries,2,3 and by 2020 is projected to cost 
the global health economy 957 billion USD per year.4 
As the atherosclerotic plaque progresses, the vascular 
lumen becomes narrowed, thereby reducing delivery of 
blood and oxygen to the target organ, resulting in isch-
emia. Ultimately, advanced plaques may become unsta-
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clinically as myocardial infarction, stroke, or critical limb 
ischemia, depending on anatomic location.5,6 Although 
current treatments have conferred some benefit result-
ing in reduced incidence and mortality of cardiovascular 
disease, new therapies are still needed to address the 
residual risk.7
Noncoding RNAs are a class of RNA molecules involved 
in a wide range of pathophysiological processes and hold 
major potential in cardiovascular disease, with techniques 
to manipulate their expression constantly evolving.6,8 They 
are usually categorized by their size and function, and the 
best studied are microRNA and long noncoding RNA 
(lncRNA).9 MicroRNAs are 20 to 22 nucleotides in length 
and characteristically form a hairpin structure.10 They act 
through post-transcriptional silencing of mRNA and have 
particular importance in atherosclerosis.11 Notably, miR-
126 correlates well with extent of atherosclerosis,12,13 and 
when delivered in vivo, reduces atherosclerosis burden in 
high-cholesterol diet mice.14 Additionally, miR-155 has 
an atheroprotective role, possibly through anti-inflam-
matory mechanism.15 In fact, numerous microRNAs are 
now implicated in lipid handling,16,17 and the behaviors of 
smooth muscle cell (SMC)18,19 and endothelial cells20–22 in 
atherosclerosis, and their use as biomarkers is extensively 
researched.12,23,24
lncRNAs are less well-studied and characterized than 
microRNAs, having been described more recently and 
are more complex in their form and functions. LncRNA 
are >200 nucleotides in length, can form complex sec-
ondary structures, and have a range of functions which 
can impact on gene regulation, such as acting as guides, 
sponges, or decoys.25,26
Recently, roles for lncRNAs in cardiovascular health 
have been emerging. A study of lncRNAs in 414 patients 
with myocardial infarction detected increases in aHIF, 
KCNQ1OT1, MALAT1, and MIAT, whereas ANRIL was 
decreased compared with controls.27 Similarly, LIPCAR 
is an important lncRNA that is highly expressed in, and 
predictive of future outcome following myocardial infarc-
tion.28 Furthermore, the lncRNA meXis, which is critical 
in cholesterol efflux in macrophages, is important in 
many stages in the pathogenesis of cardiovascular dis-
eases.29 Although several such lncRNAs correlate with 
atherosclerosis disease burden,30–32 and others appear 
to be important in vascular cell behavior,33,34 there is no 
evidence to-date of a lncRNA which regulates or con-
trols plaque instability.
We hypothesized that lncRNAs are dynamically 
involved in unstable atherosclerotic plaque pathology and 
aimed to discover and characterize novel lncRNAs, which 
represent feasible targets for new therapies, based on 
publicly available RNA sequencing databases.
MATERIALS AND METHODS
The data that support the findings of this study are available 
from the corresponding author upon reasonable request.
RNA Sequencing Analysis
For sample and library preparation, see Gene Expression 
Omnibus database: GSE120521. Data were analyzed using 
RSEM and DESeq2 packages to derive fragments per kilo-
base million, fold change, and P values. Filtering was performed 
using Microsoft Excel for Mac, version 16.35
Carotid Artery Plaque Samples for RNA
Excised carotid plaque tissue was harvested from patients 
undergoing carotid endarterectomy following acute neurovas-
cular event. Local ethical approval was obtained via the NHS 
Lothian BioResource Tissue Governance committee (15/
ES/0094). As described previously in Mahmoud et al,35 plaques 
were assessed macroscopically for dissection into stable and 
Nonstandard Abbreviations and Acronyms
FISH fluorescent in situ hybridization
FITC fluorescein isothiocyanate
GCRL1 gastric cancer–related lncRNA 1
IFN interferon
IL interleukin
ISH in situ hybridization
JC Jurkat cells
LDL low-density lipoprotein
lncRNA long noncoding RNA
LOX-1  lectin-like oxidized low-density lipopro-
tein receptor-1
M-CSF macrophage colony-stimulating factor
MLN myoregulin
oxLDL oxidized low-density lipoprotein
PELATON  plaque enriched lncRNA in atherosclerotic 
and inflammatory bowel macrophage 
regulation
ROS reactive oxygen species
SMIM-25 small membrane integral protein 25
SNORD3 small nucleolar RNA, C/D box 3A
SRA scavenger receptor class A)
TNF tumor necrosis factor
Highlights
• PELATON (plaque enriched lncRNA in athero-
sclerotic and inflammatory bowel macrophage 
regulation) is a novel long noncoding RNA upregu-
lated in unstable atherosclerotic plaque.
• PELATON is highly specific to monocytes and 
macrophages and is expressed in the nucleus.
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unstable sections. Areas of plaque rupture with associated 
intraplaque hemorrhage were considered unstable, and rela-
tively healthy adjacent sections taken to be stable. Samples 
were stored in RNA later (Sigma-Aldrich) for 30 to 60 min-
utes, before snap freezing and storage at −80°C, until use for 
downstream validation of RNA sequencing candidates. Patient 
characteristics are described below (Table 1).
Normal Aortic Samples for RNA Analysis
Aortic tissue was harvested from patients undergoing coro-
nary bypass grafting, with no known aortic disease. Local ethi-
cal approval was obtained via the NHS Lothian BioResource 
Tissue Governance committee (15/ES/0094). Punch biopsy 
samples taken from grafting sites were stored in RNA later 
(Sigma-Aldrich), for 30 to 60 minutes, before being snap-fro-
zen and stored at −80°C until use.
Human Carotid Plaque Sections for ISH/IHC
Human atherosclerotic plaque samples were obtained from 
patients undergoing carotid endarterectomy. The tissue was 
part of the Maastricht Pathology Tissue Collection, and col-
lection, storage, and use of tissue and patient data were 
performed in agreement with the Dutch Code for Proper 
Secondary Use of Human Tissue, the Declaration of Helsinki 
and was approved by the local Medical Ethical Committee 
(protocol number 16-4-181). Immediately after resection, 
each atheroma was divided into parallel segments of 5 mm. 
Formalin-fixed segments were stained with hematoxylin-eosin 
and according to Virmani et al,5 fibrous cap atheroma with or 
without intraplaque hemorrhage, termed stable or unstable 
respectively, used for in situ hybridization (ISH)/IHC. Patient 
characteristics were described previously.36
Cell Culture
Peripheral blood mononuclear cells were isolated from whole 
blood of anonymized healthy control subjects, for use in frac-
tionation RNA–fluorescent in situ hybridization (FISH), phago-
cytosis, and efferocytosis assays, with local ethical approval 
(15/HV/013). All studies were approved by East and West 
Scotland Research Ethics Committees, and all experiments 
were conducted according to the principles expressed in the 
Declaration of Helsinki.Leucosep porous membrane separation 
tubes (Greiner Bio-One GmbH, Germany) were used to iso-
late peripheral blood mononuclear cells, and monocytes were 
isolated by positive selection performed with lyophilized CD14 
microbeads (Miltenyi Biotech, Gladbach, Germany). Peripheral 
blood mononuclear cells utilized in high-content analysis were 
isolated by Ficoll-Paque gradient, using buffy coat samples 
from Uniklinik RWTH Aachen, Germany.
For differentiation to macrophages, monocytes were cul-
tured for 1 week at 37°C, 5% CO2, and stimulated with 10 
ng/mL M-CSF (macrophage colony-stimulating factor; 
Immunotools, Friesoythe, Germany) in RPMI 1640 Glutamax 
(Life Technologies, the Netherlands, Europe) supplemented 
with 10% FBS (Gibco/Thermo Fisher, United Kingdom) and 
1% Pen/Strep (Gibco), with one medium change after 4 days of 
culture. SMCs and endothelial cells included in cell expression 
panel were cultured using supplemented SMC Growth Medium 
2 (PromoCell, Heidelberg, Germany) and endothelial cell 
growth medium (EGM-2 BulletKit; Lonza, Basel, Switzerland) 
respectively, at 37°C, 5% CO2.
GapmeR Knockdown
For selective knockdown of PELATON (plaque enriched 
lncRNA in atherosclerotic and inflammatory bowel macrophage 
regulation), GapmeRs were designed using a sequence com-
mon to all isoforms (Table IV in the online-only Data Supplement) 
(Exiqon, Denmark). GapmeRs were resuspended with RNase 
free water to a stock concentration of 10 μM and frozen at −20°C 
until use. Macrophages were transfected with Lipofectamine 
RNAiMax (Thermo Fisher Scientific) with GapmeR concentra-
tion of 20 nM for 6 hours, followed by quiescence for 18 hours.
Table 1. Carotid Endarterectomy Patient Characteristics
Carotid Endarterectomy Patients (n=5)
Age in years, mean (SD) 74 (7.1)
Men, n (%) 5 (100)
Systolic BP, mm Hg, mean (SD) 144 (15.2)
Diastolic BP, mm Hg, mean (SD) 86 (15.4)
Presenting syndrome, n (%)
 Stroke 2 (40)
 TIA/amaurosis fugax 4 (80)
Cardiovascular history, n (%)
 Ischemic heart disease 3 (60)
 Myocardial infarction 0 (0)
Risk factors
 Hypertension 3 (60)
 Diabetes mellitus 0 (0)
 Hypercholesterolemia 1 (20)
 Smoker 0 (0)
Medication
 Aspirin 2 (40)
 Clopidogrel 2 (40)
 Anticoagulant 1 (20)
 Statin 3 (60)
 ACE inhibitor/ARB 1 (20)
 β-blocker 3 (60)
Hematology, mean (SD)
 Hb 146 (15.2)
 WBC 7.2 (0.9)
 PLT 236 (32)
Biochemistry, mean (SD)
 Creatinine, mmol/L 85.6 (22.3)
 Total cholesterol, mmol/L 4.4 (1.1)
 HDL 1.2 (0.45)
 LDL 2.3 (0.88)
 Trig 1.9 (1.3)
Carotid endarterectomy patient demographics, clinical presentation, past med-
ical history, and serum parameters. Data presented as mean and either SD (SD) 
or percentage (%) in brackets, as stated. ACE indicates angiotensin-converting 
enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; Hb, ; HDL, high-
density lipoprotein; LDL, low-density lipoprotein; PLT, ; TIA, transient ischemic 
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Human Tissue Panel
A commercially available human tissue panel, Human MTC 
Panel I (Takara clontech), was used to characterize expression 
of PELATON.
Macrophage Polarization
Macrophages were polarized into 4 different subtypes, M1, 
M2a, M2b, and MoxLDL (foam cells), achieved by incubation 
for 24 hours at 37°C with the relevant stimuli for each; IFN 
(interferon) γ 20 ng/mL and lipopolysaccharide 10 ng/mL for 
M1; IL (interleukin)-4 for M2a at 50 ng/mL; IL-10 at 10 ng/
mL for M2c and human oxLDL (oxidized low-density lipopro-
tein) at 50 μg/mL for MoxLDL (Table VII in the online-only 
Data Supplement). Polarization was confirmed by quantitative 
real-time polymerase chain reaction for subtype-specific mark-
ers (M1, CD68; M2a, CD200R; M2b, CD163; MoxLDL, iNOS 
[inducible nitric oxide synthase])
RNA Isolation
Total RNA was isolated from human tissue and cultured cells 
using the miRNEasy kit (Qiagen). Tissue disruption was per-
formed in 700 μL of Qiazol for each sample using TissueLyser II 
(Qiagen) for normal aortic samples and pestle and mortar in liq-
uid nitrogen for carotid plaque samples. As per standard protocol, 
chloroform was added for separation of RNA fraction, which was 
precipitated in alcohol, and washed on minicolumns before elu-
tion in RNase free water. RNA quantity and purity was assessed 
using Nanodrop 1000 spectrophotometer (Thermo Scientific, 
Paisley, United Kingdom), confirming 260/280 ratio of 1.6 to 
2.2 for all samples. Samples were stored at −80°C until required.
Gene Expression Analysis
For quantitative gene expression analysis, cDNA was prepared 
from total RNA using the Multiscribe Reverse Transcriptase 
kit (Life Technologies, Paisley, United Kingdom). Quantitative 
real-time polymerase chain reaction was performed using 
SYBR green (Life Technologies) and custom PCR primers 
(Eurofins MWG, Ebersberg, Germany) or Taqman Master Mix 
(Applied Biosystems) with Taqman probes (primer and probe 
sequences; Tables I and II in the online-only Data Supplement). 
UBC (ubiquitin C) was used as housekeeping gene for normal-
ization. Relative quantifications were calculated by using the 
2-ΔΔCT method.37 When undetermined, a cycle threshold of 
40 was used arbitrarily.
Cellular Fractionation for PELATON Localization
Fractionation of monocytes and macrophages was carried out 
using the Ambion PARIS kit (Thermo Fisher, United Kingdom), 
as per the manufacturer’s guidelines. Cells were initially treated 
with cell fractionation buffer, resulting in a nuclear and cyto-
plasmic fraction. Nuclear material was further subjected to cell 
disruption buffer and then both fractions processed for RNA 
isolation using a column purification method.
Cloning and In Vitro Translation
Open reading frame sequences from PELATON and 
LINC00948 were incorporated into pcDNA 3.1 (+) vectors 
(Geneart, Thermo Fisher), with Kozak sequence upstream, and 
hemagglutinin tag downstream and flanking restriction enzyme 
sites (Table III in the online-only Data Supplement). Translation 
potential was assessed using the PURExpress In Vitro Protein 
Synthesis Kit (New England Biolabs, MA).
Western Blot
Protein lysates were prepared in Novex Tricine sodium dodec-
ylsulfate (SDS) sample buffer (Thermo Fisher Scientific, MA) 
and dithiothreitol, incubated at 85°C, centrifuged briefly, and 
loaded onto a Novex 10% to 20% Tris-Glycine Mini Gel, 
alongside a the Spectra low range multicolor protein ladder 
(1.7–40 kDa range). Electrophoresis was performed at 120 V, 
300A, for 1 hour, in Novex Tris-Glycine SDS Running Buffer. 
Membrane transfer was carried out in a Mini Blot transfer mod-
ule at 20 V, 300A for 1 hour in Novex Tris-Glycine Transfer 
Buffer. Membranes were incubated overnight at 4°C with anti-
hemagglutinin-tag (ab9110, 1/1000; Abcam). After washing, 
membranes were incubated with the appropriate Licor IRDye 
680 secondary antibody (1:10 000) at room temperature for 1 
hour. Following additional washing, protein levels were visual-
ized via Licor.
High-Content Analysis
For all assays primary human monocytes were seeded at a 
density of 75 to 100 000 cells per well in Corning Falcon 
96-Well Imaging Microplates (Fisher Scientific). In the initial 
high-content analysis, 7-day differentiation into macrophages 
was performed, and cells were then transfected with LNA 
GapmeR targeting PELATON, as described above. Functional 
assays were then carried out and are described below. In each 
case Hoechst nuclear staining was used to identify nuclei, and 
images were acquired using BD Pathway 855 High Content 
Bioimager (BD Biosciences, CA). Nine images were taken of 
each individual well. Using Attovision software, stitched images 
were corrected for background variations, and Attovision cell 
segmentation (Polygon based on Hoechst signal) was carried 
out using appropriate threshold, watershed and object size 
in- and exclusion criteria. Data were further analyzed using 
DIVA software (BD Biosciences) to enable quantification of 
output parameters.
Apoptosis of macrophages was first assessed at 24 hours 
post-transfection (baseline) and after a further 24 hours 
treatment with 300 nM staurosporine (Sigma, Dorset, United 
Kingdom) for chemical induction of apoptosis. Apoptosis was 
detected by binding of Annexin-V-OG (locally prepared, cour-
tesy of C. Reutelingsperger MUMC) at 2.5 ng/mL, incubated 
for 15 minutes at 37°C in binding buffer. Images were acquired, 
and apoptotic cells expressed as a proportion of total cells.
Phagocytosis was assessed by incubation with pHrodo Red 
Zymosan Bioparticles (Life Technologies) at 5 μL in 150 μL per 
well for 1 hour. Cells shown to have positive uptake of the par-
ticles were considered positive and expressed as a percentage 
of total cells in each well. For validation experiments, the same 
protocol was used, but images acquired with the Operetta High-
Content Imaging System (Perkin-ElmerOH) and image analysis 
was performed using Columbus (Perkin-Elmer, OH) software. 
Image analysis produced an image that pseudo labeled cells 
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Lipid uptake was assessed by incubation with a mixture of 
0.8 μg oxLDL (derived locally) and 0.2 μg Topfluor (Avanti Polar 
Lipids, AL) for 3 hours. Cells with uptake of Topfluor and oxLDL 
were expressed as a percentage of total cells in each well.
Mitochondrial stress was induced using 1.2 μM stauro-
sporine for 2 hours. Mitotracker mitochondrial stain (Thermo 
Fisher, United Kingdom) was then added at 250 nM and cells 
incubated for 30 minutes. Reduced mitochondrial membrane 
potentials result in less uptake of Mitotracker and so a lower 
signal intensity. Relative average intensity was compared 
between wells.
Reactive oxygen species (ROS) production was stimulated 
using 10 μM menadione (Sigma, Dorset, United Kingdom) for 
30 minutes, and ROS were detected with 20 μM dichloro-
fluorescin diacetate (Invitrogen, CA). ROS-positive cells were 
expressed as a percentage of total cells per well.
Efferocytosis Assay
Monocytes were differentiated to macrophages and trans-
fected with LNA GapmeR, as described previously. Jurkat cells 
(JC; Supplier Maastricht) were induced to undergo apoptosis 
by incubation with 20 nM Staurosporine for 1.5 hours at 37°C, 
then labeled with Calcein (Thermo Fisher). The macrophages 
were incubated with the JC for 1 hour and washed thoroughly. 
Macrophages were then detached on ice with 0.05% EDTA 
in PBS and run on an Attune NxT Flow Cytometer to quan-
tify the percentage of cells which have taken up the Calcein 
labeled JC (fluorescein isothiocyanate [FITC]+ cells) with 
analysis performed on FlowJo software. Apoptosis of JC was 
confirmed with Annexin V.
In Situ Hybridization + Immunohistochemistry
For ISH, formalin-fixed, paraffin-embedded tissue sec-
tions were firstly deparaffinized and rehydrated by washing 
in Xylene for 5 minutes, followed by sequential washes in 
100%, 96%, and 70% ethanol, respectively, for 5 minutes 
each, then washed in water, followed by PBS for 5 minutes. 
The microRNA buffer set (Qiagen, 339450) was then used, 
providing proteinase K for tissue digestion (incubated 1:1000 
at 37°C for 4 minutes) and hybridization buffer, which was 
used to dilute the ISH probes (Table V in the online-only Data 
Supplement) to 25 nM. The ISH probes were incubated on 
the sections overnight at 55°C, sealed using coverslips and 
rubber glue to prevent drying out. The sections were washed 
with 5× saline-sodium citrate buffer at 55°C and room tem-
perature to increase hybridization specificity. Subsequently, 
the sections were washed with PBS and incubated with 
digoxigenin wash and block buffer set (11585762001; 
Roche) for 1 hour, which was subsequently used to dilute anti-
digoxigenin-AP (11093274910; Roche) at 1:500 and left for 
1 hour at room temperature. After washing with tris-buffered 
saline and Tween, NBT/BCIP AP tablets (11697471001; 
Roche) were used for detection to visualize probe in the pres-
ence of levamisole to reduce background staining (Vector 
Laboratories, Peterborough, United Kingdom). Detection 
occurred at ≈3 hours. For immunohistochemistry costaining, 
slides were incubated in 0.3% hydrogen peroxide for 15 min-
utes, washed with tris-buffered saline and Tween 0.1% BSA, 
before incubation in 5% goat serum for 1 hour. Antibodies 
were then added (Table VI in the online-only Data Supplement) 
for 30 minutes, before washes with tris-buffered saline, and 
incubation with anti–mouse-HRP Brightvision (Immunologic, 
the Netherlands) for 30 minutes. After tris-buffered saline 
washes, Polydetector HRP green kit (Bio SB, CA), 1 drop 
in 2 mL was added to tissues and allowed to develop for 3 
minutes. After rinsing with water, tissues were counterstained 
with nuclear fast red (Sigma-Aldrich), before further wash-
ing. Rehydration was done with sequential washes of 70%, 
96%, and 100% ethanol, respectively, followed by xylene and 
mounting with Pertex.
RNA–Fluorescent In Situ Hybridization
Custom RNA-FISH probe sets were generated to the full 
sequence of PELATON (Thermo Fisher Scientific). Monocytes 
were differentiated to macrophages as previously described, 
grown on 16-mm coverslips for 1 week, before being 
washed in PBS and fixed in 4% paraformaldehyde. RNA-
FISH was performed according to manufacturer’s instruc-
tions (ViewRNA cell FISH, ThermoFisher Scientific). Briefly, 
the coverslips were permeabilized using detergent QS and 
digested in protease solution at 1:4000, then incubated with 
a probe sets at 1:100 (PELATON, SNORD3 [small nucleolar 
RNA, C/D box 3A] and UBC). The coverslips were then sub-
sequently incubated with preamplifier, and amplifier, before 
finally being incubated with the label probe, which provides 
the fluorescent signal. Coverslips were then mounted onto 
glass slides using Prolong Gold Antifade Mounting Medium 
with DAPI (Vector Laboratories).
Microscopy
An Axioscan slidescanner (ZEISS) was used to image both 
in situ and immunofluorescence, using Zen software (ZEISS). 
All settings for the Axioscan and software were optimized and 
then maintained for each set of experiments so that sections 
can be compared accurately. RNA-FISH was imaged using the 
Andor Revolution XDi spinning disk confocal microscope.
Pseudo Fluorescent Image Analysis
Bright-field images for PELATON (Purple in situ staining) 
and CD68/aSMA (green immunohistochemistry staining) 
in human plaque were converted into pseudo fluorescent 
images using Image J Software. Images were opened in 
Image J, and the color deconvolution tool used, selecting 
regions of interest for each stain (Purple in situ staining, 
green immunohistochemistry staining, and pink nuclear red 
counterstain), generating RGB values for each color and split-
ting the images into these components. The RGB values gen-
erated for each color were kept consistent for further analysis 
across all samples. Once the images were split into the 3 col-
ors, the nuclear stain was discounted so that the in situ and 
immunohistochemistry staining could be seen clearly. These 
were then inverted and given pseudo colors of red and green, 
respectively, and the resulting images merged to create a dual 
fluorescent image.
Statistical Analysis
Statistical analyses were performed according to figure leg-
ends using Graphpad Prism version 8.0. Data are expressed 
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Shapiro-Wilks test. Statistical difference between 2 groups 
was assessed using 2-tailed unpaired or paired t test for 
parametric data and Mann-Whitney or Wilcoxon-matched 
pairs signed-rank tests for nonpaired and paired nonparamet-
ric data, respectively. One-way ANOVA±multiple comparisons 
were used for ≥3 groups. Post hoc testing with Dunnett test 
has been performed as appropriate. Statistical significance 
is indicated when P value of <0.05 (*P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001).
Graphical Image Construction
Graphical images were generated using basic components 
from Elsevier Medical Art.
RESULTS
Identification of Dysregulated LncRNAs in RNA 
Sequencing of Stable Versus Unstable Plaque
To identify lncRNAs relevant to plaque stability, we uti-
lized RNA sequencing data from stable versus unstable 
human carotid endarterectomy specimens previously 
generated in our group, with 50 million read depth 
(Gene Expression Omnibus database: GSE12052135). 
From a total of 58 037 genes annotated in the human 
genome (GRCh38), 18 101 genes were detectable 
across both groups. Of these, 1822 were considered to 
be differentially expressed once stringent filtering cri-
teria of log2 fold change ≤ −1.0 or ≥ 1.0 and P<0.01 
were applied. Protein-coding genes accounted for the 
majority 1655 (90.8%), the remainder comprised of 
135 (7.4%) lncRNAs, 30 (1.6%) pseudogenes, and 2 
(0.001%) small RNAs (Figure 1A). For further validation 
of the dataset, the panel of dysregulated protein-coding 
genes was analyzed for Gene Ontology term enrich-
ment. The top 200 terms for upregulated coding genes 
corresponded largely with immune system processes 
and inflammation (Figure 1B), whereas downregulated 
genes were involved mainly in muscle system processes 
as expected (Figure 1C). Further expression filtering 
of the lncRNAs using fragments per kilobase million 
threshold of >5 subsequently identified 47 candidates, 8 
upregulated and 39 downregulated (Figure 1D). The top 
5 upregulated and downregulated candidate lncRNAs 
are shown (Figure 1E).
PELATON Is a Nuclear, Monocyte/Macrophage-
Specific Transcript
The read profiles of the top differentially regulated 
lncRNAs were assessed to validate RNA sequenc-
ing data. This analysis revealed that the top upregu-
lated lncRNA, RP11-294N21.2, was a false positive, 
as read coverage extends outside the annotation, and 
thus likely corresponds to background signal emanating 
from the nearby intron of MAPRE2 and was therefore 
excluded from further analysis (Figure I in the online-
only Data Supplement). The second most upregulated 
lncRNA, LINC01272, was then chosen for valida-
tion and further investigation. We named LINC01272 
PELATON (for PELATON), and will be subsequently 
referred to as such throughout this article. The read 
profile of PELATON is consistent with the upregula-
tion in unstable plaque and shows the expression of a 
4 exon-transcript, corresponding to the longest anno-
tated isoform (203, ENST0000425497.5; Figure 2A). 
Each isoform shares a common region at the start of 
the final exon, which was subsequently used for primer 
and GapmeR design (dashed box, Figure 2A). From the 
RNA sequencing dataset, PELATON expression was 
4.6-fold higher (log2 fold change 2.2) in the unstable 
condition (P=2.36×10-8, Figure 2B), and this differ-
ential expression was further confirmed in a quantita-
tive real-time polymerase chain reaction validation set 
of n=5 independently samples carotid plaque samples 
(P=0.02, Figure 2C). Additionally, normal aortic tis-
sue, without atherosclerosis, had significantly reduced 
PELATON expression when compared with unstable 
plaque (P=0.05, Figure 2D).
To determine the potential relevance of PELATON 
to plaque development, its cell specificity and cellular 
localization was assessed. A panel of relevant cell types, 
including immune cells, SMCs, and endothelial cells of 
multiple origins, demonstrated that PELATON expres-
sion is very high in monocytes and macrophages but 
barely expressed by other common vascular cell types 
(Figure 2E). A panel of healthy human tissues demon-
strated highest expression of PELATON in spleen, adi-
pose tissue, and liver (Figure 2F), all macrophage-rich 
tissues, consistent with the cell panel findings. Mac-
rophages were differentiated into different subtypes 
(M1, M2a, M2c, and MoxLDL), and their polarization 
confirmed by modulation of appropriate markers in the 
expected direction and fold change (Figure II in the 
online-only Data Supplement). PELATON expression 
was unaltered across most subtypes but was signifi-
cantly reduced in M1 macrophages, suggesting that 
PELATON may have a subtype-specific functional role 
in macrophages (Figure 2G). Inflammatory markers 
IL-6, IL-1, IL-1β, and TNF (tumor necrosis factor) α 
were, however, unchanged (Figure III in the online-only 
Data Supplement). Cellular fractionation experiments 
in both monocytes and monocyte-derived macro-
phages revealed that PELATON was localized predom-
inantly within the nucleus (91% and 98%, respectively; 
Figure 2H and 2I). This data was further corroborated 
by RNA-FISH for PELATON alongside cytoplasmic/
nuclear (UBC) and nuclear only (SNORD3) markers, 
which confirmed the nuclear localization of PELA-
TON in monocyte-derived macrophages (Figure 2J, 
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Figure 1. Selection of long noncoding RNA (lncRNA) candidates from RNA sequencing in stable vs unstable carotid plaque.  
A, Filtering strategy applied to derive a shortlist of 47 significantly dysregulated lncRNAs. Gene Ontology term enrichment analysis of (B) 
upregulated and (C) downregulated protein-coding genes. D, Heatmap showing differentially expressed lncRNAs within 4 patient samples 
(as row Z score of the Log2 [fragments per kilobase million (FPKM)+1]). E, Top 5 lncRNAs significantly upregulated and downregulated from 
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Figure 2. Characterization of PELATON (plaque enriched lncRNA in atherosclerotic and inflammatory bowel macrophage 
regulation).  
A, Relative read coverage of PELATON in unstable vs stable plaque from RNA sequencing, with corresponding annotated exonic structure below. 
The graph displays normalized read count using the same scale between stable and unstable samples for each patient (scale indicated on the right 
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PELATON Localizes to Necrotic-, Inflammatory-, 
and Macrophage-Rich Areas of Atherosclerotic 
Plaque
To further confirm the localization and cell-type expres-
sion of PELATON within the plaque, we undertook in situ 
hybridization with simultaneous immunostaining of macro-
phages (CD68) or SMCs (αSMA) in atherosclerotic plaque 
excised at carotid endarterectomy from n=3 patients. 
Nonspecific in situ hybridization probe (Scramble) and IgG 
immunohistochemistry control antibodies were negative, 
confirming probe and antibody specificity (Figure V in the 
online-only Data Supplement). Pseudo fluorescent images 
were produced in Image J to allow for better visualization 
of costaining (Figures 3D through 3F and 3J through 3L). 
PELATON localizes to regions adjacent to the necrotic 
core and plaque shoulder (Figure 3A through 3F). CD68 
consistently colocalized with PELATON on same tissue 
staining (Figure 3B, 3E, 3H, and 3K), and there was only a 
slight PELATON signal in the αSMA-positive SMC layers 
(Figure 3C, 3F, 3I, and 3J). This data, therefore, provide 
in vivo confirmation PELATON expression described in 
vitro in of the cell panel, as PELATON is predominately 
expressed in lesional macrophages. This thereby suggests 
a potential functional role for PELATON in atherogenesis.
PELATON Is a LncRNA Not a Protein-Coding 
Gene
Although PELATON was identified as a lncRNA in our 
screening approach, it has been previously annotated 
with multiple names, including RP11-290F20.3, GCRL1 
(gastric cancer–related lncRNA 1)38 and SMIM-25 
(small membrane integral protein 25). To clarify if PELA-
TON has any protein-coding potential, the putative open 
reading frame NP_001265584, as predicted by Refseq, 
was inserted into a pcDNA 3.1(+) vector with a hemag-
glutinin tag and cloned for in vitro translation assay (Fig-
ure 4A). Sequencing of the resultant plasmid confirmed 
the intended base pair sequence was present, along with 
the transcription start site and standard Kozak sequence 
upstream. The plasmid was then inserted into a propri-
etary in vitro translation kit, with all the cellular compo-
nents necessary for translation contained. Successful 
transcription of mRNA was detected for both PELATON 
and our positive control by quantitative real-time poly-
merase chain reaction (Figure 4B and 4C; using prim-
ers across the ORF sequence and hemagglutinin tag 
boundary), but PELATON transcript was not translated 
to a peptide, confirmed by Western blotting. A positive 
control, LINC00948 known to encode the micropeptide 
MLN (myoregulin),39 indeed encoded a peptide of the 
expected size of 5 kDa (Figure 4D). In addition, bioin-
formatic predictions of protein-coding probability univer-
sally indicate noncoding is most likely (Figure 4E).40–44 
Together, this data supports the noncoding nature of 
PELATON, further confirming it as a bona fide lncRNA.
PELATON Does Not Act in cis
As several lncRNAs are known to act on nearby genes 
at the same locus (in cis), neighboring genes on chro-
mosome 20 were further analyzed for regulation when 
PELATON levels were reduced by interference (Fig-
ure 5A).45 The protein-coding gene CEBPB, occupying 
a locus 74 kb upstream from PELATON, is implicated in 
the human immune response, and in macrophage func-
tion, and was, therefore, a potential candidate for PELA-
TON regulation.46 However, none of the genes in a 1 
megabase span around PELATON were observed to be 
dysregulated in monocyte-derived macrophages under 
PELATON knockdown conditions (Figure 5B through 5I).
Knockdown of PELATON in Macrophages 
Impairs Macrophage Function In Vitro
To assess the role of PELATON in macrophage behavior 
and function, a GapmeR knockdown approach was used 
(Figure 6A). Two GapmeRs were designed to target a 
common sequence in all PELATON isoforms, with both 
GapmeRs achieving a reduction in expression of 53% 
to 62% that were subsequently used for all assays (Fig-
ure 6B). High-content image analysis established that 
PELATON knockdown did not change macrophage cell 
area, cell perimeter, mitochondrial stress, baseline apop-
tosis, apoptosis stimulated by staurosporine, or base-
line ROS production (Figure VI in the online-only Data 
Supplement). However, there was a reduction in mena-
dione stimulated ROS production at 30 minutes (Fig-
ure 6C), uptake of oxLDL (Figure 6D), and phagocytosis 
Figure 2 Continued. B, PELATON expression (as fragments per kilobase million) in stable vs unstable plaque based on the RNA sequencing 
analysis. The P value of 2.36×10−8 was obtained using DESeq2 based on the raw read count. C, Relative quantification of PELATON 
expression determined by quantitative real-time polymerase chain reaction (qRT-PCR) in additional samples of stable and unstable plaque 
obtained by qRT-PCR (P=0.02, t test, paired, 2-tailed). D, qRT-PCR of PELATON in expression normal aortic samples compared with unstable 
plaque. PELATON expression determined by qRT-PCR across (E) panel of vascular cell types (F) a panel of human tissues. G, PELATON 
expression across a panel of macrophage phenotypes (Ctrl [control macrophages], M1, M2a, M2c, foam cells). Cellular fractionation by qRT-
PCR demonstrates cellular localization of PELATON in monocytes (H) and macrophages (I), using NEAT1 as nuclear control (n=3 technical 
replicates). J, RNA–fluorescent in situ hybridization in monocyte-derived macrophages of PELATON. Cytoplasmic/nuclear (UBC [ubiquitin C]) 
and nuclear (SNORD3 [small nucleolar RNA, C/D box 3A]) markers used as controls. Scale bar represents 5 µm. Statistical analysis by Mann-
Whitney test and paired t test. Ao indicates aortic; CAEC, coronary artery endothelial cells; CASMC, coronary artery smooth muscle cells; 
HSVEC, human saphenous vein endothelial cells; NEAT1, nuclear paraspeckle assembly transcript1; PAEC, pulmonary artery endothelial cells; 
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Figure 3. In situ hybridization and immunohistochemistry in atherosclerotic plaque with pseudo fluorescent images.  
PELATON (plaque enriched lncRNA in atherosclerotic and inflammatory bowel macrophage regulation) expression (purple A–C, G–I, Red 
D–F, J–L) is enriched alongside the necrotic core and plaque shoulders. PELATON colocalized with CD68 (green; B, E, H, K), but not with 
αSMA (green) (C, F, I, J). Pseudo fluorescent images (D–F, J–L) were produced with Image J, to allow for clearer visualization of PELATON 
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(Figure 6E). Further validation in an independent assay of 
phagocytosis was carried out via pHrodo Zymosan parti-
cle uptake, modeling phagocytosis of large particles, such 
as protein aggregates or erythrocytes (Figure 6F through 
6H). The pHrodo Zymosan particles become fluorescent 
once within the phagosome, seen in Figure 6G and 6H. 
These images were analyzed with Columbus software, to 
provide automatic quantification, detecting the presence 
of macrophages positive (green) and negative (red) for 
bead uptake (Figure VII in the online-only Data Supple-
ment). This assay confirmed the findings of Figure 6E, 
with PELATON knockdown causing a consistent reduc-
tion in phagocytosis (Figure 6F). Conversely, phagocytosis 
did not affect PELATON levels (Figure VIII in the online-
only Data Supplement). To assess if other forms of 
endocytosis were affected, we performed an assay of 
efferocytosis, the uptake of apoptotic macrophages, 
using fluorescently labeled JC which had undergone 
apoptosis. Under these conditions, PELATON knock-
down did not affect efferocytosis (Figure 6I, Figure IX in 
the online-only Data Supplement), unlike phagocytosis. 
CD36 is a key receptor in oxLDL uptake and phagocyto-
sis, both of which were altered by PELATON knockdown. 
To determine if CD36 could be involved in the mecha-
nism of action for PELATON, its expression in control and 
PELATON knockdown conditions was assessed. This 
Figure 4. PELATON (plaque enriched lncRNA in atherosclerotic and inflammatory bowel macrophage regulation) does not 
encode a micropeptide.  
A, PELATON predicted open reading frame (ORF; blue) appended with a hemagglutinin (HA) tag (yellow) was inserted into pcDNA 3.1(+) 
plasmid for in vitro translation assay. LINC00948 was used as a positive control, known to encode the micropeptide MLN (myoregulin). RNA 
expression using customized primers spanning ORF/HA boundary confirming transcription into RNA from plasmids by (B) quantitative real-time 
polymerase chain reaction (PCR) and (C) agarose gel electrophoresis of PCR products. D, Western blot using HA-antibody to detect tagged 
peptide produced by in vitro translation. E, Prediction scores estimating probability of protein-coding potential. M blank+L blank denotes 
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demonstrated that PELATON knockdown results in a 
39% reduction in CD36 expression (Figure 6J). Further-
more, we interrogated the RNA sequencing results from 
the initial patient samples of stable and unstable carotid 
artery plaque (Figure 1) for CD36 expression and deter-
mined there was a strong positive correlation (R2=0.9287, 
P=0.0001) between PELATON and CD36 (Figure 6K). 
This strengthens the findings from the knockdown exper-
iment that the mechanism of PELATON action may be 
due to modulation of CD36. Taken together these data 
confirm that PELATON depletion has a functional impact 
on human macrophages.
DISCUSSION
Based on available RNA sequencing data in human 
carotid endarterectomy samples, we have identified 
and characterized the novel lncRNA PELATON, which 
is enriched in unstable atherosclerosis, and expressed 
almost entirely in the nuclear fraction of monocytes and 
macrophages. Depletion of PELATON in monocyte-
derived macrophages in vitro markedly reduces the cell’s 
ability to perform phagocytosis. Phagocytosis of lipopro-
teins or erythrocytes is integral to plaque progression and 
strongly associated with development of plaque instabil-
ity.47 Our research suggests that this lncRNA contributes 
further to the growing body of evidence that the noncod-
ing genome is fundamentally involved in wide-ranging 
pathologies, including atherosclerotic vascular disease.
The previous paired-sample design of RNA sequenc-
ing was key in ensuring the discovery of differentially 
expressed lncRNAs in atherosclerotic plaque. Utiliz-
ing paired stable and unstable samples from the same 
patient overcomes the inherent variability in gene 
expression between human subjects, which may oth-
erwise mask significant fold changes. This is particu-
larly important in lowly expressed transcripts, such as 
lncRNAs, when absolute copy numbers per cell may 
be lower than protein-coding genes.48 Furthermore, a 
high read-depth enabled accurate alignment of reads to 
the most recent human genome annotation (GRCh38). 
Notably, lncRNAs represent a relatively small proportion 
of all of the differentially expressed genes (7.4%), and 
protein-coding genes predominate (90.8%), as would be 
Figure 5. Effect of PELATON (plaque enriched lncRNA in atherosclerotic and inflammatory bowel macrophage regulation) 
knockdown on nearby genes a.  
A, Neighboring genes upstream and downstream to PELATON within a 1 megabase. B–I, Effects of GapmeR knockdown on the expression 
of neighboring protein-coding genes by quantitative real-time polymerase chain reaction in monocyte-derived macrophages. n=3 biological 
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Figure 6. Effects of PELATON (plaque enriched lncRNA in atherosclerotic and inflammatory bowel macrophage regulation) 
knockdown on macrophage function.  
A, Schematic of high-content analysis workflow. B, GapmeR knockdown of PELATON in monocyte-derived macrophages. In high-content 
analysis, PELATON knockdown has a significant effect on (C) reactive oxygen species production after menadione induction, (D) oxidized LDL 
(low-density lipoprotein) uptake, and (E) phagocytosis. All HCA assays (C–K) performed in 5 wells per condition, 9 images per well, and n=2, 
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expected in these atherogenic, proinflammatory condi-
tions. Gene Ontology analysis of the most dysregulated 
protein-coding genes provides further validation of the 
RNA sequencing output, demonstrating an increase in 
terms related to inflammatory and immune processes in 
the unstable tissue, whereas muscle cell processes were 
down (Figure 1B and 1C). Though these groupings are 
typically broad, a reduction in the smooth muscle fibrous 
cap is characteristic in instability, as is enhanced infiltra-
tion by inflammatory cells.49,50
Given that the samples used for RNA sequencing 
were of a heterogeneous cellular composition, the 
cell-specific expression of PELATON needed to be 
determined. Both in vitro and in situ analysis allowed 
us to confirm that PELATON is highly specific to 
monocytes and macrophages (Figure 2E and 6) and 
is localized to the nucleus (Figures 2H through 2J). 
This specificity of expression, along with its abundant 
expression, suggests that PELATON is a functionally 
important lncRNA to the monocyte and macrophage 
population. Interestingly, although PELATON has been 
identified in several studies of other inflammatory 
conditions, it has never been fully characterized. In a 
biomarker study by Wang et al,51 PELATON expres-
sion was upregulated in tissue and plasma of patients 
with inflammatory bowel disease, and similarly Lin et 
al38 found it to be upregulated in tissue and plasma of 
patients with gastric cancer, As with other well-known 
lncRNAs, it is likely that biological significance is not 
limited to just one disease process, but more likely 
multiple, especially given the ubiquity of monocytes 
and macrophages in human disease.
To localize PELATON in human atherosclerotic 
plaques, staining of PELATON by in situ hybridization 
was undertaken alongside immunohistochemistry for 
macrophage marker CD68 and SMC marker αSMA 
(Figure 3). These findings confirm that PELATON is 
most enriched in areas where macrophages are known 
to aggregate, and least apparent in smooth muscle and 
adventitial layers, with predominantly nuclear intracellular 
localization. It is important to note that although colocal-
ization with CD68 is extremely frequent, it is on occa-
sion not exclusive. Instances where PELATON is present 
without CD68, are likely explained by several possibili-
ties. Within the atherosclerotic plaque, there are hetero-
geneous macrophage populations, of which not all types 
will express CD68. Furthermore, SMCs undergoing phe-
notypic switching may also express macrophage markers 
like CD68, but not PELATON. On contrary, there may be 
monocytes that have not yet differentiated and thus will 
not express CD68 but may express PELATON.
With new genomic annotations, protein-coding poten-
tial is sometimes assigned to sites previously designated 
as noncoding, which is relevant in the case of several 
recent discoveries.39,52 In addition, micropeptides ema-
nating from lncRNA transcripts may be implicated in 
their mechanism of action and are very likely to affect 
the overall function of the gene, but require experimen-
tal validation.39,53 In the case of PELATON, although it 
was historically named as LINC01272 on Ensembl, it has 
also been referred to as GCRL1 and further renamed 
as SMIM-25 based on Refseq’s prediction of a possible 
encoded peptide NP_001265584. Due to the critical 
nature of this point, we demonstrate that the putative 
protein-coding sequence contained within the final 
2 exons of PELATON is not translated into a peptide, 
under the experimental conditions we used. In addition, 
bioinformatics tools were all uniform, predicting PELA-
TON to be noncoding (Figure 4).
Discovery of the functional significance of novel 
lncRNAs is challenging given their extremely wide-rang-
ing functions.26 Furthermore, atherosclerosis is a com-
plex disease, given the numerous different cell types 
involved, pathophysiological pathways occurring in paral-
lel, and the myriad of crosstalk between cells and organic 
compounds. LncRNAs can commonly act to affect gene 
in cis; however, nearby genes were unaffected by PELA-
TON knockdown (Figure 5). Our high-content analysis 
approach was hence designed to screen a number of 
well-known macrophage functions relevant to athero-
sclerosis. GapmeRs were used to knockdown PELATON 
expression, as they are the tool of choice for nuclear 
transcripts.54 GapmeR knockdown of PELATON had 
no effect on general cell size (area and perimeter) nor 
apoptosis (Figure VI in the online-only Data Supplement). 
However, key atherosclerosis processes of phagocyto-
sis, oxLDL uptake, and ROS production were markedly 
affected by GapmeR knockdown of PELATON (Fig-
ure 6C through 6E). Impairment of phagocytosis upon 
knockdown of PELATON was further validated in an 
independent assay (Figure 6F through 6H), whereas the 
specific pathway of efferocytosis was unaltered (Fig-
ure 6I, Figure IX in the online-only Data Supplement). 
It is particularly noteworthy that these dysregulated pro-
cesses are closely linked and are all central to plaque 
macrophage pathophysiologies, such as foam cell devel-
opment, inflammation upregulation, and the progression 
of the plaque to a vulnerable and unstable phenotype.
Figure 6 Continued. (3 biological replicates on different days, 11 to 14 wells per condition, 9 to 21 images per well assessed). Hoechst 
nuclear stain allows for cell detection. Representative images of (G) GapmeR control and (H) PELATON knockdown wells. I, Efferocytosis 
quantification following PELATON knockdown, calculated by the percentage of cells that have taken up Calcein labeled jurkat cells that had 
undergone apoptosis. J, Effect of PELATON knockdown on expression levels of CD36. K, Correlation of PELATON with CD36 expression in 
plaque based on fragments per kilobase million (FPKM) value from RNA sequencing data. Statistical analysis by 1-way ANOVA and multiple 
comparisons. FITC+ indicates fluorescein isothiocyanate positive cells; hdPBMC indicates human-derived peripheral blood mononuclear cells; 
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The overall effect of phagocytosis in the plaque is 
complex, with opposing effects at different stages. In 
the early plaque environment, phagocytosis may be ben-
eficial, as macrophages are the principal phagocytes of 
apoptotic cells (including apoptotic macrophages) and in 
doing so can reduce lesion size. As the lesion progresses, 
the potentially helpful process of dead cell removal is by 
far outweighed by the negative remodeling achieved by 
sequestration of erythrocytes, platelets, and modified lipo-
proteins. Thus, any modulation of this process to attempt to 
reduce the rate of plaque formation would have to be tightly 
regulated, and understanding the precise method of action 
of PELATON, and how it affects these pathways, would be 
essential before PELATON can be targeted in a clinical 
setting. Dying cells and various forms of LDL (oxLDL, acet-
ylated LDL, aggregated LDL) are recognized by receptors 
including CD36, CD68, SRA (scavenger receptor class 
A), and LOX-1 (lectin-like oxidized low-density lipoprotein 
receptor-1).47 Interestingly, CD36 expression significantly 
reduces with PELATON knockdown (Figure 6J), further 
confirming that PELATON is involved in regulating this 
pathway. Utilizing the RNA sequencing data from stable 
and unstable sections of carotid artery plaque, we were 
able to demonstrate a strong positive correlation of PELA-
TON and CD36 expression (Figure 6K), backing up the 
in vitro data from Figure 6J. Lipid uptake transforms the 
macrophage into a foam cell, which ultimately undergoes 
necrotic or apoptotic cell death and empties its contents 
into the enlarging necrotic core. Macrophages and foam 
cells are also key producers of ROS, as well as proinflam-
matory cytokines and MMPs, which additionally promul-
gate the inflammatory cascade.55 A lncRNA that positively 
regulates phagocytosis, such as PELATON, represents a 
potential target for reducing the rate of this process and 
hence plaque progression. To our knowledge, there are 
no such therapies in development at present. Local deliv-
ery of an anti-PELATON oligonucleotide such as a Gap-
meR would be preferred over systemic delivery, to avoid 
off-target effects. As such, coronary artery plaques are 
easily accessible percutaneously, and administration dur-
ing angioplasty using a drug-eluting balloon, for example, 
would allow treatment of specific lesions.
Further mechanistic analysis of how PELATON exerts 
its effects on macrophage behavior is now critical, to 
understand how potential therapies could work, and 
how modulation would impact other pathways within the 
plaque and the organism as a whole. The finding that 
PELATON knockdown causes a reduction in CD36 
mRNA (Figure 6K) confirms that PELATON has the 
ability to modulate receptors in key macrophage func-
tions, further backing up the importance of these future 
investigations. Additional experiments will be expansive 
and beyond the scope of the current article. We conclude 
that PELATON represents an exciting lncRNA discovery, 
with biological significance in the functions of the macro-
phage and potential applications in treatment of inflam-
matory conditions such as atherosclerosis. Further work 
to define disease-specific functions and mechanistic 
interactions is now critical to take these findings forward.
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Table 2. Normal Aorta Patient Characteristics
Normal Aorta Patients (n=3)
Age in years, mean (SD) 65 (7.2)
Men, n (%) 3 (100)
Cardiovascular history, n (%)
 Ischemic heart disease 3 (100)
 Myocardial infarction 3 (100)
Risk factors
 Hypertension 2 (67)
 Diabetes mellitus 2 (67)
 Hypercholesterolemia 2 (67)
 Smoker 0 (0)
Medication
 Aspirin 0 (0)
 Clopidogrel 0 (0)
 Anticoagulant 0 (0)
 Statin 1 (34)
 ACE inhibitor/ARB 1 (34)
 B-blocker 1 (34)
Hematology, mean (SD)
 Hb 122 (17.0)
 WBC 8.7 (5.4)
 PLT 254 (45)
Biochemistry, mean (SD)
 Creatinine, mmol/L 79 (6.9)
 Total cholesterol, mmol/L 4.0 (1.1)
 HDL 1.1 (0.1)
 LDL 2.1 (0.8)
 Trig 1.7 (0.9)
Normal aorta patient demographics, clinical presentation, past medical history, 
and serum parameters. Data presented as mean and either SD or percentage 
(%) in brackets, as stated. ACE indicates angiotensin-converting enzyme; ARB, 
angiotensin receptor blocker; Hb, ; HDL, high-density lipoprotein; LDL, low-den-
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